Japan's Dainippon, S. Korea's Bukwang Ink Lonasen Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma says it has licensed its Lonasen (blonanserin) schizophrenia drug to Bukwang Pharmaceutical in South Korea